These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23909006)

  • 1. Peak experiences of psilocybin users and non-users.
    Cummins C; Lyke J
    J Psychoactive Drugs; 2013; 45(2):189-94. PubMed ID: 23909006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
    Griffiths RR; Richards WA; McCann U; Jesse R
    Psychopharmacology (Berl); 2006 Aug; 187(3):268-83; discussion 284-92. PubMed ID: 16826400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
    Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
    Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
    Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
    J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students.
    Hallock RM; Dean A; Knecht ZA; Spencer J; Taverna EC
    Drug Alcohol Depend; 2013 Jun; 130(1-3):245-8. PubMed ID: 23265089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.
    Noorani T; Garcia-Romeu A; Swift TC; Griffiths RR; Johnson MW
    J Psychopharmacol; 2018 Jul; 32(7):756-769. PubMed ID: 29938565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
    Studerus E; Kometer M; Hasler F; Vollenweider FX
    J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
    Carbonaro TM; Bradstreet MP; Barrett FS; MacLean KA; Jesse R; Johnson MW; Griffiths RR
    J Psychopharmacol; 2016 Dec; 30(12):1268-1278. PubMed ID: 27578767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perceived harm, motivations for use and subjective experiences of recreational psychedelic 'magic' mushroom use.
    Roberts CA; Osborne-Miller I; Cole J; Gage SH; Christiansen P
    J Psychopharmacol; 2020 Sep; 34(9):999-1007. PubMed ID: 32674668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
    Griffiths R; Richards W; Johnson M; McCann U; Jesse R
    J Psychopharmacol; 2008 Aug; 22(6):621-32. PubMed ID: 18593735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
    Barrett FS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.
    Barrett FS; Bradstreet MP; Leoutsakos JS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2016 Dec; 30(12):1279-1295. PubMed ID: 27856683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic Functional Hyperconnectivity After Psilocybin Intake Is Primarily Associated With Oceanic Boundlessness.
    Mortaheb S; Fort LD; Mason NL; Mallaroni P; Ramaekers JG; Demertzi A
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 Jul; 9(7):681-692. PubMed ID: 38588855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study.
    van Elk M; Fejer G; Lempe P; Prochazckova L; Kuchar M; Hajkova K; Marschall J
    Psychopharmacology (Berl); 2022 Jun; 239(6):1705-1720. PubMed ID: 33928421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.
    Sumnall HR; Cole JC; Jerome L
    J Psychopharmacol; 2006 Sep; 20(5):670-82. PubMed ID: 16401654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
    Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
    Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.
    Carter OL; Pettigrew JD; Hasler F; Wallis GM; Liu GB; Hell D; Vollenweider FX
    Neuropsychopharmacology; 2005 Jun; 30(6):1154-62. PubMed ID: 15688092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Quite a Profoundly Strange Experience": An Analysis of the Experiences of Salvia divinorum Users.
    Hutton F; Kivell B; Boyle O
    J Psychoactive Drugs; 2016; 48(3):206-13. PubMed ID: 27176133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.